SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]
SEC Accession No. 0001213900-24-024838
Filing Date
2024-03-21
Accepted
2024-03-21 17:13:14
Documents
8
Period of Report
2024-03-21

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO FORM 6-K ea0202338-6ka1_xtlbio.htm 6-K/A 17309
2 NOTICE AND PROXY STATEMENT WITH RESPECT TO THE COMPANY'S EXTRAORDINARY GENERAL M ea020233801ex99-1_xtlbio.htm EX-99.1 119803
3 PROXY CARD FOR HOLDERS OF ORDINARY SHARES WITH RESPECT TO THE COMPANY'S EXTRAORD ea020233801ex99-2_xtlbio.htm EX-99.2 41722
4 VOTING INSTRUCTION CARD FOR AMERICAN DEPOSITARY SHARE HOLDERS WITH RESPECT TO TH ea020233801ex99-3_xtlbio.htm EX-99.3 1414
5 GRAPHIC ex99-1_001.jpg GRAPHIC 3212
6 GRAPHIC ex99-2_001.jpg GRAPHIC 3212
7 GRAPHIC ex99-3_001.jpg GRAPHIC 541465
8 GRAPHIC ex99-3_002.jpg GRAPHIC 328795
  Complete submission text file 0001213900-24-024838.txt   1388861
Mailing Address 5 HACHAROSHET ST. RAANANA L3 4365603
Business Address XTL BIOPHARMACEUTICALS LTD C/O ALSTON & BIRD LLP, 90 PARK AVENUE NEW YORK NY 10016 972 9 955 7080
XTL BIOPHARMACEUTICALS LTD (Filer) CIK: 0001023549 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3
Type: 6-K/A | Act: 34 | File No.: 001-36000 | Film No.: 24772295
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)